DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Asia-Pacific pharmaceutical manufacturing industry will grow by 14.8% annually with a total addressable market cap of $1,034.6 billion over 2021-2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.

This report is based on a comprehensive research of the entire Asia-Pacific pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:

• Industry Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Industry Opportunities
• Porter's Fiver Forces

The trend and outlook of Asia-Pacific industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia-Pacific pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.

Key Players

• Abbott Laboratories
• Aenova Group
• Amgen
• AstraZeneca
• Catalent Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences
• GlaxoSmithKline plc
• Johnson & Johnson
• Lonza Group
• Lupin
• Merck & Co. Inc.
• Novartis AG
• Novo Nordisk
• Pfizer, Inc.
• Roche
• Sanofi SA
• Takeda

Key Topics Covered:

1 Introduction

2 Industry Overview and Dynamics

2.1 Industry Size and Forecast

2.1.1 Impact of COVID-19 on World Economy

2.1.2 Impact of COVID-19 on the Industry

2.2 Major Growth Drivers

2.3 Industry Restraints and Challenges

2.4 Emerging Opportunities and Industry Trends

2.5 Porter's Fiver Forces Analysis

3 Segmentation of Asia Pacific Industry by Formulation

3.1 Industry Overview by Formulation

3.2 Tablets

3.3 Capsules

3.4 Injectable

3.5 Sprays

3.6 Suspensions

3.7 Powders

3.8 Other Formulations

4 Segmentation of Asia Pacific Industry by Route of Administration

4.1 Industry Overview by Route of Administration

4.2 Oral Medicine

4.3 Topical Medicine

4.4 Parenteral Medicine

4.5 Inhalations

4.6 Other Routes of Administration

5 Segmentation of Asia Pacific Industry by Age Group

5.1 Industry Overview by Age Group

5.2 Children & Adolescents

5.3 Adults

5.4 Geriatric

6 Segmentation of Asia Pacific Industry by Therapeutic Application

6.1 Industry Overview by Therapeutic Application

6.2 Cardiovascular Diseases

6.3 Pain

6.4 Diabetes

6.5 Cancer

6.6 Respiratory Diseases

6.7 Neurological Diseases

6.8 Orthopedics

6.9 Other Applications

7 Segmentation of Asia Pacific Industry by Drug Type

7.1 Industry Overview by Drug Type

7.2 Branded Prescription Drugs

7.3 Generic Prescription Drugs

7.4 OTC Drugs

8 Segmentation of Asia Pacific Industry by Distribution Channels

8.1 Industry Overview by Distribution Channels

8.2 Retail Channels

8.3 Non-retail Channels

9 Segmentation of Asia Pacific Industry by Manufacturing Facility

9.1 Industry Overview by Manufacturing Facility

9.2 In-house Facility

9.3 Outsourced Facility

10 Asia-Pacific Industry 2020-2027 by Country

10.1 Overview of Asia-Pacific Industry

10.2 China

10.3 Japan

10.4 India

10.5 Australia

10.6 South Korea

10.7 Rest of APAC Region

11 Competitive Landscape

11.1 Overview of Key Vendors

11.2 New Product Launch, Partnership, Investment, and M&A

11.3 Company Profiles

12 Investing in Asia Pacific Industry: Risk Assessment and Management

12.1 Risk Evaluation of Asia Pacific Industry

12.2 Critical Success Factors (CSFs)

For more information about this report visit https://www.researchandmarkets.com/r/n50pal

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900